OncoGenex Pharmaceuticals

Type: Company
Name: OncoGenex Pharmaceuticals
First reported 20 hours ago - Updated 20 hours ago - 1 reports

Stocks Hitting 52-Week Lows

Targacept (NASDAQ: TRGT) shares reached a new 52-week low of $2.90 after the company announced its plans to discontinue TC-5214 overactive bladder program.Education Management (NASDAQ: EDMC) shares fell 9.93% to touch a new 52-week low of $1.27. Education ... [Published Benzinga.com - 20 hours ago]
First reported Jul 24 2014 - Updated Jul 24 2014 - 2 reports

OncoGenex to Report Financial Results for Second Quarter 2014 on August 7, 2014

To access the webcast, log on to the Investor Relations page of the OncoGenex website at www.oncogenex.com. Alternatively, you may access the live conference call by dialing (877) 606-1416 (U.S. & CanadaABOUT ONCOGENEXOncoGenex is a biopharmaceutical ... [Published Industrial Info Financials - Jul 24 2014]
First reported Jul 21 2014 - Updated Jul 22 2014 - 2 reports

Shares of OncoGenex Pharmaceutical Has Fallen Below Previous 52-Week Low

Written on Tue, 07/22/2014 - 2:48pmBy Amy SchwartzOncoGenex Pharmaceutical ( NASDAQ:OGXI ) traded at a new 52-week low today of $3.03. Approximately 50,000 shares have changed hands today, as compared to an average 30-day volume of 243,000 shares.OncoGenex ... [Published Comtex SmarTrend - Jul 22 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

OncoGenex Pharmaceuticals Hits New 12-Month Low at $3.25 (OGXI)

OncoGenex Pharmaceuticals (NASDAQ:OGXI)’s share price reached a new 52-week low on Tuesday , AnalystRatings.NET reports. The stock traded as low as $3.25 and last traded at $3.31, with a volume of 210,884 shares changing hands. The stock had previously ... [Published American Banking News - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 2 reports

OncoGenex's Apatorsen in Phase II for Lung Cancer

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into ... [Published Zacks.com - Jul 07 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Q2 In Review: Fire, Fundings, Floating Wind, Biotech Ups and Downs

Happy Fourth of July, everyone. Here’s a review of some notable Xconomy Seattle stories from the second quarter. Enjoy the holiday weekend!Ahead of Amazon’s smartphone announcement, Curt Woodward looked at why the company wanted to build one in the first ... [Published Xconomy - Jul 03 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

OncoGenex Opens Enrollment for Lung Cancer Trial

OncoGenex Pharmaceuticals Inc. announced initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating apatorsen in previously untreated patients with advanced squamous cell lung cancer. Apatorsen is ... [Published Drug Discovery and Development - Jul 02 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 2 reports

OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell..

BOTHELL, Wash.Approximately 140 patients with previously untreated stage IV or recurrent squamous cell lung cancers or stage IIIB squamous cell cancers that are not amenable to radiochemotherapy will be randomized to receive either apatorsen plus gemcitabine ... [Published ADVFN UK - Jul 01 2014]
First reported Jun 26 2014 - Updated Jun 27 2014 - 2 reports

OncoGenex prices offering

16:42 ET | About: OncoGenex Pharmaceuticals Inc. (OGXI)OncoGenex Pharmaceuticals (OGXI +2.6%) offers 5,559,866 Series A units and 1,340,538 Series B units for public sale. Each Series A unit consist of one share of common stock plus one warrant to purchase ... [Published Seeking Alpha - Jun 27 2014]
First reported Apr 28 2014 - Updated Apr 29 2014 - 4 reports

OncoGenex falls on Phase III CRPC miss

OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) fell $5.85 (60%) to $3.85 on Monday after the company and partner Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said first-line treatment with IV custirsen (OGX-011) plus docetaxel and prednisone missed. ... [Published BioPortfolio - Apr 29 2014]
First reported Apr 28 2014 - Updated Apr 29 2014 - 3 reports

OncoGenex Phase 3 prostate cancer trial fails

Top-line survival results of OncoGenex Pharmaceuticals’ (NASDAQ:OGXI) Phase 3 SYNERGY trial indicate that the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement ... [Published BioPortfolio - Apr 29 2014]
First reported Apr 23 2014 - Updated Apr 23 2014 - 3 reports

FDA Fast Tracks OncoGenex Drug for Prostate Cancer

OncoGenex Pharmaceuticals Inc. announced that the U.S. Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: NEXT ARTICLE More From BioPortfolio on "FDA Fast Tracks OncoGenex Drug for Prostate Cancer"Search BioPortfolio ... [Published BioPortfolio - Apr 23 2014]

Quotes

...Lead, Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London and the primary investigator on the trial. "Given the depth of preclinical evidence supporting the utility of apatorsen in a broad range of cancers, we are excited to open enrollment in the Cedar trial to shed greater light on the ability of apatorsen to reduce resistance to chemotherapies and improve survival outcomes for patients with squamous cell lung cancer."
...to bring Stewart onto our Board during such an important stage in Sangamo's development," said Edward Lanphier , Sangamo's president and CEO. "As we expand our manufacturing capabilities and advance ZFP Therapeutic(®) programs for the development of genetic cures for monogenic diseases, Stewart's proven entrepreneurial and executive leadership skills and extensive experience in AAV gene therapy, particularly cGMP manufacturing and clinical development, will be very valuable to Sangamo."
...He founded the company three decades ago and turned it into the world's biggest gold producer. "You can take, maybe, Munk out of Barrick. You can't take Barrick out of Munk" he said at the company's annual meeting of shareholders. ( http://r.reuters.com/rud98v )
NEXT ARTICLE More From BioPortfolio on "OncoGenex and Teva’s prostate cancercancer drug fails in Ph III study"

More Content

All (56) | News (40) | Reports (0) | Blogs (13) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
Stocks Hitting 52-Week Lows [Published Benzinga.com - 20 hours ago]
OncoGenex to Report Financial Results for Secon... [Published Industrial Info Financials - Jul 24 2014]
OncoGenex to Report Financial Results for Secon... [Published PR Newswire: Health - Jul 24 2014]
Shares of OncoGenex Pharmaceutical Has Fallen B... [Published Comtex SmarTrend - Jul 22 2014]
OncoGenex Pharmaceuticals Sets New 1-Year Low a... [Published American Banking News - Jul 21 2014]
OncoGenex Pharmaceuticals Hits New 12-Month Low... [Published American Banking News - Jul 08 2014]
OncoGenex's Apatorsen in Phase II for Lung Cancer [Published Zacks.com - Jul 07 2014]
OncoGenex initiates Phase II squamous cell lung... [Published Individual.com - Jul 07 2014]
Q2 In Review: Fire, Fundings, Floating Wind, Bi... [Published Xconomy - Jul 03 2014]
OncoGenex Opens Enrollment for Lung Cancer Trial [Published Drug Discovery and Development - Jul 02 2014]
OncoGenex Announces Cedar™ Clinical Trial Evalu... [Published ADVFN UK - Jul 01 2014]
OncoGenex Announces Cedar™ Clinical Trial Evalu... [Published PR Newswire: Health - Jul 01 2014]
Boeing boss didn’t make our list, but did top a... [Published Seattle Times - Jun 29 2014]
OncoGenex raises $24 million [Published BioPortfolio - Jun 28 2014]
ONCOGENEX PHARMACEUTICALS, INC. FILES (8-K) Dis... [Published TVNewsCheck - Jun 27 2014]
OncoGenex prices offering [Published Seeking Alpha - Jun 27 2014]
Video: Monday Sector Laggards: Biotechnology, E... [Published IT Business Net - Jun 27 2014]
ONCOGENEX PHARMACEUTICALS, INC. FILES (8-K) Dis... [Published Street Sweeper - Jun 26 2014]
OncoGenex Pharmaceuticals Announces Pricing of ... [Published BusinessWeek - Jun 26 2014]
OncoGenex Pharmaceuticals Announces Pricing of ... [Published Financial Services - Jun 26 2014]
Sangamo BioSciences Appoints H. Stewart Parker ... [Published HispanicBusiness.com - Jun 26 2014]
Sangamo BioSciences appoints H. Stewart Parker ... [Published Center Watch - Jun 20 2014]
Transitional Cell Cancer Urothelial Cell Cancer... [Published BioPortfolio - May 28 2014]
OncoGenex Retrenches and Searches for Answers A... [Published BioPortfolio - May 22 2014]
Fast track designation granted to OncoGenex Pha... [Published BioPortfolio - May 13 2014]
The Zacks Analyst Blog Highlights:Endocyte, Aco... [Published PR Newswire: Financial Services - May 08 2014]
OncoGenex prostate cancer therapy drug fails Ph... [Published BioPortfolio - May 06 2014]
The Feuerstein-Ratain Rule Update: Still Perfec... [Published The Street Latest - May 06 2014]
Frontrunning: May 1 [Published Zero Hedge - May 01 2014]
OncoGenex Pharmaceuticals, Inc. Reports Financi... [Published Financial Services - Apr 30 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
OncoGenex to Report Financial Results for Secon... [Published PR Newswire: Health - Jul 24 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, July 24, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's second quarter 2014 financial results will be released on Thursday, August 7, 2014, and that ...
OncoGenex Announces Cedar™ Clinical Trial Evalu... [Published PR Newswire: Health - Jul 01 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, July 1, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced initiation of the Cedar™ clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating ...
The Zacks Analyst Blog Highlights:Endocyte, Aco... [Published PR Newswire: Financial Services - May 08 2014]
CHICAGO, May 8, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured ...
Frontrunning: May 1 [Published Zero Hedge - May 01 2014]
Two-Thirds of Insurance Exchange Enrollees Paid Premiums ( WSJ ) Panic: Criminal Charges Against Banks Risk Sparking Crisis ( BBG ) Did the junk bubble pop: Junk Loans Pulled as Investors Say No After Fed Raises Concerns ( BBG ) CME mulls price fluctuation ...
OncoGenex to Report Financial Results for First... [Published PR Newswire: Health - Apr 28 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, April 28, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's first quarter 2014 financial results will be released on Wednesday, April 30, 2014, and that ...
1 2 3

Press Releases

sort by: Date | Relevance
OncoGenex Pharmaceuticals Announces Pricing of ... [Published Financial Services - Jun 26 2014]
OncoGenex Pharmaceuticals, Inc. Reports Financi... [Published Financial Services - Apr 30 2014]
OncoGenex Pharmaceuticals, Inc. Reports Financi... [Published Financial Services - Mar 11 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.